Llwytho...
Euglycemic DKA (euDKA) as a presentation of COVID‐19
COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients.
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Clin Case Rep |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley and Sons Inc.
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7753533/ https://ncbi.nlm.nih.gov/pubmed/33362928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3540 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|